Parathyroid tumors

Current Treatment Options in Oncology

Volumn 4, Issue 4, 2003, Pages 319-328

  Carling, Tobias ^b   Udelsman, Robert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Hypercalcemia; Main Drug Interaction; Parathyroid Adenoma; Parathyroid Gland; Primary Hyperparathyroidism

Indexed keywords

ARTICLE; HUMAN; PARATHYROID TUMOR;

HUMANS; PARATHYROID NEOPLASMS;

EID: 0642304823     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0007-x     Document Type: Article

References (29)

1. Carling T: Molecular pathology of parathyroid tumors. Trends Endocrinol Metab 2001, 12:53–58. DOI: 10.1016/S1043-2760(00)00345-3
2. Lundgren E, Rastad J, Åkerström G, Ljunghall S: Population-based health screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997, 121:287–294. DOI: 10.1016/S0039-6060(97)90357-3
3. Melton LJ 3rd: The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res 2002, 17(Suppl 2):N12-N17.
4. Marx SJ, Simonds WF, Agarwal SK, et al.: Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res 2002, 17(Suppl 2):N37-N43.
5. Chattopadhyay N, Mithal A, Brown EM: The calciumsensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocrine Rev 1996, 17:289–307. DOI: 10.1210/er.17.4.289
6. Carling T, Rastad J, Szabo E, et al.: Reduced vitamin D receptor mRNA levels in parathyroid glands of primary and secondary hyperparathyroidism. J Clin Endocrinol 2000, 85:2000–2003. DOI: 10.1210/jc.85.5.2000
7. Farnebo F, Enberg U, Grimelius L, et al.: Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J Clin Endocrinol Metab 1997, 82:3481–3486. DOI: 10.1210/jc.82.10.3481
8. Carling T, Kindmark A, Hellman P, et al.: Vitamin D receptor genotypes in primary hyperparathyroidism. Nat Med 1995, 1:1309–1311. DOI: 10.1038/nm1295-1309
9. Carpten JD, Robbins CM, Villablanca A, et al.: HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002, 32:676–680. DOI: 10.1038/ng1048
10. Bilezikian J, Potts JJ, Fuleihan GH, et al.: Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002, 87:5353–5361. A summary of a recent workshop by the National Institutes of Health on asymptomatic primary hyperparathyroidism. The paper reflects a consensus by worldwide experts in endocrinology and surgery. DOI: 10.1210/jc.2002-021370
11. Nilsson I, Yin L, Lundgren E, et al.: Clinical presentation of primary hyperparathyroidism in Europe--nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002, 17(Suppl 2):N68-N74. This article presents a comprehensive epidemiologic analysis of essentially all patients operated on for parathyroid adenoma during 40 years in Sweden and includes 102,515 observed person-years. An increased risk of excess mortality caused by cardiovascular disease, diabetes mellitus, and urogenital is substained. The study further indicates that a modern, more liberal approach, to operative intervention normalizes the risk of death in these patients.
12. Silverberg S, Shane E, Jacobs T, et al.: A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999, 341:1249–1255. DOI: 10.1056/NEJM199910213411701
13. Utiger R: Treatment of primary hyperparathyroidism. N Engl J Med 1999, 341:1301–1302. DOI: 10.1056/NEJM199910213411709
14. Marx SJ: Familial hypocalciuric hypercalcemia. In Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism. Edited by Favus MJ. Philadelphia: Lippincott-Raven; 1996:90–192.
15. Carling T, Szabo E, Bai M, et al.: Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 2000, 85:2042–2047. DOI: 10.1210/jc.85.5.2042
16. Peacock M: Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res 2002, 17(Suppl 2):N87-N94.
17. Udelsman R: Parathyroid imaging: the myths and the reality. Radiology 1996, 201:317–318.
18. Alexander HR Jr, Chen CC, Shawker T, et al.: Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl 2):N133-N140.
19. Udelsman R, Aruny JE, Donovan PI, et al.: Rapid parathyroid hormone analysis during venous localization. Ann Surg 2003, in press.
20. O’Herrin J, Weigel T, Wilson M, Chen H: Radioguided parathyroidectomy via VATS combined with intraoperative parathyroid hormone testing: the surgical approach of choice for patients with mediastinal parathyroid adenomas? J Bone Miner Res 2002, 17:1368–1371. DOI: 10.1359/jbmr.2002.17.8.1368
21. Udelsman R: Surgery in primary hyperparathyroidism: the patient without previous neck surgery. J Bone Miner Res 2002, 17(Suppl 2):N126-N132.
22. Stojadinovic A, Shaha A, Orlikoff R, et al.: Prospective functional voice assessment in patients undergoing thyroid surgery. Ann Surg 2002, 236:823–832. DOI: 10.1097/00000658-200212000-00015
23. Udelsman R: Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg 2002, 235:665–670. DOI: 10.1097/00000658-200205000-00008
24. Henry J, Iacobone M, Mirallie E, et al.: Indications and results of video-assisted parathyroidectomy by a lateral approach in patients with primary hyperparathyroidism. Surgery 2001, 130:999–1004. DOI: 10.1067/msy.2001.119112
25. Rao D, Agarwal G, Talpos G, et al.: Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 2002, 17(Suppl 2):N75-N80.
26. van der Wielen R, Lowik M, van den Berg H, et al.: Serum vitamin D concentrations among elderly people in Europe. Lancet 1995, 346:207–210. DOI: 10.1016/S0140-6736(95)91266-5
27. http://www.micromedex.com. Accessed February, 2003.
28. Antoniucci D, Shoback D: Calcimimetics in the treatment of primary hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl 2):N141-N145.
29. Collins M, Skarulis M, Bilezikian J, et al.: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998, 83:1083–1088. DOI: 10.1210/jc.83.4.1083